Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity

v3.24.1.1.u2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Preferred Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Non-Controlling Interest
Beginning balance, common (in shares) at Mar. 31, 2021   89,790,086            
Beginning balance at Mar. 31, 2021 $ 145,112 $ 10 $ 100 $ (71) $ 373,310 $ (903) $ (227,334) $ 0
Beginning balance, preferred (in shares) at Mar. 31, 2021     100,000          
Beginning balance, treasury (in shares) at Mar. 31, 2021       758,125        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net (loss) income 35,569           35,546 23
Foreign currency translation (39,395)         (38,438)   (957)
Stock-based compensation expense 19,970       19,970      
Shares issued:                
Exercise of stock options (in shares)   1,311,098            
Exercise of stock options 4,300       4,300      
Issuance of restricted shares and vesting of restricted units (in shares)   287,218            
Shares for acquisition of Fyber (in shares)   5,775,299            
Shares for acquisition of Fyber 356,686       356,686      
Acquisition of non-controlling interests in Fyber 2,578             2,578
Payment of withholding taxes related to the net share settlement of equity awards (8,605)       (8,605)      
Ending balance, common (in shares) at Mar. 31, 2022   97,163,701            
Ending balance at Mar. 31, 2022 516,215 $ 10 $ 100 $ (71) 745,661 (39,341) (191,788) 1,644
Ending balance, preferred (in shares) at Mar. 31, 2022     100,000          
Ending balance, treasury (in shares) at Mar. 31, 2022       758,125        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net (loss) income 16,870           16,673 197
Foreign currency translation (2,386)         (2,604)   218
Stock-based compensation expense 31,245       31,245      
Shares issued:                
Exercise of stock options (in shares)   966,536            
Exercise of stock options 2,020       2,020      
Issuance of restricted shares and vesting of restricted units (in shares)   122,150            
Shares for acquisition of Fyber (in shares)   1,205,982            
Shares for acquisition of Fyber 50,000       50,000      
Acquisition of non-controlling interests in Fyber 0              
Payment of withholding taxes related to the net share settlement of equity awards $ (6,709)       (6,709)      
Ending balance, common (in shares) at Mar. 31, 2023 99,458,369 99,458,369            
Ending balance at Mar. 31, 2023 $ 607,255 $ 10 $ 100 $ (71) 822,217 (41,945) (175,115) 2,059
Ending balance, preferred (in shares) at Mar. 31, 2023 100,000   100,000          
Ending balance, treasury (in shares) at Mar. 31, 2023 758,125     758,125        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net (loss) income $ (420,448)           (420,228) (220)
Foreign currency translation (6,271)         (7,010)   739
Stock-based compensation expense $ 35,562       35,562      
Shares issued:                
Exercise of stock options (in shares) 1,223,630 1,050,553            
Exercise of stock options $ 2,871       2,871      
Issuance of restricted shares and vesting of restricted units (in shares)   1,610,010            
Acquisition of non-controlling interests in Fyber (3,751)       (1,173)     (2,578)
Payment of withholding taxes related to the net share settlement of equity awards $ (1,286)       (1,286)      
Ending balance, common (in shares) at Mar. 31, 2024 102,118,932 102,118,932            
Ending balance at Mar. 31, 2024 $ 213,932 $ 10 $ 100 $ (71) $ 858,191 $ (48,955) $ (595,343) $ 0
Ending balance, preferred (in shares) at Mar. 31, 2024 100,000   100,000          
Ending balance, treasury (in shares) at Mar. 31, 2024 758,125     758,125